Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Cell

• Publication date

  2018-01-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2017.11.012PMID 29275866PMCID PMC5760367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

  2017cited by this paper
• p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.

  2017cited by this paper
• KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

  2017cited by this paper
• Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

  2017cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

  2016cited by this paper
• Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

  2016cited by this paper
• Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia

  2015cited by this paper
• Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

  2015cited by this paper
• Cooperative loss of RAS feedback regulation drives myeloid leukemognesis

  2015cited by this paper
• Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

  2015cited by this paper
• Age-related clonal hematopoiesis associated with adverse outcomes.

  2014cited by this paper
• Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation

  2014cited by this paper
• Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

  2014cited by this paper
• Preclinical efficacy of MEK inhibition in Nras-mutant AML.

  2014cited by this paper
• Age-related cancer mutations associated with clonal hematopoietic expansion

  2014cited by this paper
• GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  2013cited by this paper
• Clonal architecture of chronic myelomonocytic leukemias.

  2013cited by this paper
• Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness

  2013cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis

  2012cited by this paper
• Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

  2012cited by this paper
• Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

  2012cited by this paper
• ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

  2012cited by this paper
• Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

  2011cited by this paper
• Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

  2011cited by this paper
• Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

  2011cited by this paper
• TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

  2011cited by this paper
• Expression and functional role of negative signalling regulators in tumour development and progression

  2010cited by this paper
• Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

  2009cited by this paper
• Acquired mutations in TET2 are common in myelodysplastic syndromes

  2009cited by this paper
• The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.

  2009cited by this paper
• Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

  2009cited by this paper
• Intermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease

  2009cited by this paper
• Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

  2008cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Implications of NRAS mutations in AML: a study of 2502 patients.

  2006cited by this paper
• FLT3 mutations in acute myeloid leukemia cell lines

  2003cited by this paper
• Initial sequencing and comparative analysis of the mouse genome

  2002cited by this paper
• Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

  2002cited by this paper
• Initial sequencing and comparative analysis of the mouse genome.

  2002cited by this paper
• NF1 tumor suppressor gene function: narrowing the GAP.

  2001cited by this paper
• RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

  1987cited by this paper

• TET2 and TP53 Mutations Cooperatively Modulate the Response to Inflammation to Promote Leukemic Transformation

  2026cites this paper
• Toward eRASing the challenge of CMML heterogeneity

  2025cites this paper
• Co‐operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity

  2025cites this paper
• Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia

  2025cites this paper
• Establishment of CD34 + hematopoietic stem cell-derived xenograft model of hyperleukocytic acute myeloid leukemia

  2025influential citation
• PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.

  2025cites this paper
• Cigarette smoke exposure promotes nasal polyp formation through down-regulating TET2.

  2025cites this paper
• Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma

  2025cites this paper
• RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives

  2024cites this paper
• IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers

  2024cites this paper
• TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation

  2024influential citation
• Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation

  2023cites this paper
• Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemia

  2023cites this paper
• Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia

  2023cites this paper
• FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations

  2023cites this paper
• Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.

  2023cites this paper
• Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells

  2023cites this paper
• Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells

  2023cites this paper
• Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia

  2023cites this paper
• Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

  2023cites this paper
• TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway

  2023cites this paper
• Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

  2022cites this paper
• Multistep pathogenesis of chronic myelomonocytic leukemia in patients

  2022cites this paper
• Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development

  2022cites this paper
• Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes

  2022cites this paper
• FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.

  2022cites this paper
• Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis

  2022cites this paper
• Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives

  2022cites this paper
• A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

  2022cites this paper
• Murine Models of Acute Myeloid Leukemia

  2022cites this paper
• Mechanisms of Resistance to Targeted Therapies for Relapsed or Refractory Acute Myeloid Leukemia.

  2022cites this paper
• Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation

  2022cites this paper
• Chronic Myelomonocytic Leukemia Gold Jubilee

  2021cites this paper
• TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

  2021cites this paper
• EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

  2021cites this paper
• Murine Modeling of Myeloproliferative Neoplasms.

  2021cites this paper
• Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

  2021cites this paper
• Novel therapeutic targets for chronic myelomonocytic leukemia.

  2021cites this paper
• Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.

  2021cites this paper
• Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia

  2021cites this paper
• Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding

  2021cites this paper
• Diagnosis and treatment of chronic myelomonocytic leukemia

  2021influential citation
• RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

  2021cites this paper
• Unravelling the apoptotic machinery in CMML.

  2021cites this paper
• Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

  2021cites this paper
• Biallelic TET2 mutation sensitizes to 5-azacitidine in acute myeloid leukemia

  2021cites this paper
• ReviewO-GlcNAcylation: implications in normal and malignant hematopoiesis.

  2021cites this paper
• Clonal hematopoiesis and associated diseases: A review of recent findings

  2021cites this paper
• Decoding DNA methylation in epigenetics of multiple myeloma.

  2021cites this paper
• Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches

  2021cites this paper
• Establishment of a Novel CD34+ Hematopoietic Stem Cell-Derived Xenograft Model of Hyperleukocytic Acute Myeloid Leukemia

  2021influential citation
• Regulation of 5-hydroxymethylcytosine by TET2 contributes to Squamous Cell Carcinoma tumorigenesis.

  2021cites this paper
• Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia

  2021cites this paper
• Impact of RAS-Pathway Activation on Phenotype and Outcome in Patients with Chronic Myelomonocytic Leukemia and a TET2/SRSF2 Comutation

  2021cites this paper
• STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations

  2020cites this paper
• Clonal hematopoiesis: Molecular basis and clinical relevance.

  2020cites this paper
• LINC-PINT Suppresses the Aggressiveness of Thyroid Cancer by Downregulating miR-767-5p to Induce TET2 Expression

  2020cites this paper
• The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis.

  2020cites this paper
• Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients

  2020cites this paper
• TET2: A cornerstone in normal and malignant hematopoiesis

  2020cites this paper
• Loss of Tet2 affects proliferation and drug sensitivity through altered dynamics of cell-state transitions

  2020cites this paper
• ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms

  2020influential citation
• Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

  2020cites this paper
• Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration.

  2020cites this paper
• Driver mutations in acute myeloid leukemia.

  2020cites this paper
• Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

  2019cites this paper
• The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models

  2019cites this paper
• RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

  2019cites this paper
• Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia

  2019cites this paper
• RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis

  2019cites this paper
• Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management

  2019cites this paper
• Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.

  2019cites this paper
• Dysregulation of the TET family of epigenetic regulators in hematopoietic malignancies.

  2019cites this paper
• Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis

  2019influential citation
• Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics

  2019cites this paper
• Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment

  2019cites this paper
• NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis.

  2019cites this paper
• Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management

  2018cites this paper
• Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host

  2018cites this paper
• Targeting the CALR interactome in myeloproliferative neoplasms.

  2018cites this paper
• A model for RAS mutation patterns in cancers: finding the sweet spot

  2018cites this paper
• Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

  2018cites this paper
• TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors.

  2018cites this paper
• Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy

  2018cites this paper
• Loyola eCommons Loyola eCommons

  year unknowncites this paper